Literature DB >> 16918909

Regression analysis of doubly censored failure time data with frailty.

Yang-Jin Kim1.   

Abstract

In doubly censored failure time data, the survival time of interest is defined as the elapsed time between an initial event and a subsequent event, and the occurrences of both events cannot be observed exactly. Instead, only right- or interval-censored observations on the occurrence times are available. For the analysis of such data, a number of methods have been proposed under the assumption that the survival time of interest is independent of the occurrence time of the initial event. This article investigates a different situation where the independence may not be true with the focus on regression analysis of doubly censored data. Cox frailty models are applied to describe the effects of covariates and an EM algorithm is developed for estimation. Simulation studies are performed to investigate finite sample properties of the proposed method and an illustrative example from an acquired immune deficiency syndrome (AIDS) cohort study is provided.

Entities:  

Mesh:

Year:  2006        PMID: 16918909     DOI: 10.1111/j.1541-0420.2005.00487.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  4 in total

1.  Semiparametric regression analysis of doubly censored failure time data from cohort studies.

Authors:  Shuwei Li; Jianguo Sun; Tian Tian; Xia Cui
Journal:  Lifetime Data Anal       Date:  2019-05-21       Impact factor: 1.588

2.  SEMIPARAMETRIC EFFICIENT ESTIMATION FOR SHARED-FRAILTY MODELS WITH DOUBLY-CENSORED CLUSTERED DATA.

Authors:  Yu-Ru Su; Jane-Ling Wang
Journal:  Ann Stat       Date:  2016-04-11       Impact factor: 4.028

3.  Fitting Cox Models with Doubly Censored Data Using Spline-Based Sieve Marginal Likelihood.

Authors:  Zhiguo Li; Kouros Owzar
Journal:  Scand Stat Theory Appl       Date:  2015-11-23       Impact factor: 1.396

Review 4.  Interval censoring.

Authors:  Zhigang Zhang; Jianguo Sun
Journal:  Stat Methods Med Res       Date:  2009-08-04       Impact factor: 3.021

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.